Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages 1-11

  Shen, Xue ^a   Zhang, Zhongwen ^b   Zhang, Xiaoqian ^b   Zhao, Junyu ^b   Zhou, Xiaojun ^b   Xu, Qinglei ^a   Shang, Hongxia ^b   Dong, Jianjun ^c   Liao, Lin ^b  

^a SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Diabetic Nephropathy; Meta analysis; Statins

Indexed keywords

ALBUMIN; ATORVASTATIN; CERIVASTATIN; COMPACTIN; CREATININE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITROGEN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UREA;

ALBUMINURIA; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; KIDNEY FUNCTION; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; URINARY EXCRETION; BLOOD; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULUS FILTRATION RATE; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URINE;

ALBUMINURIA; BLOOD UREA NITROGEN; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84992144623     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0350-0     Document Type: Review

References (38)

1. Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet. 2014;383(9933):1947-8.
2. Guo Z, Liu X, et al. Differential urinary glycoproteome analysis of type 2 diabetic nephropathy using 2D-LC-MS/MS and iTRAQ quantification. J Transl Med. 2015;13(1):371.
3. Toneli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal fuction in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14:1605-13.
4. Guijaro C, Keane WF. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutary coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab. 1996;22(1-3):147-52.
5. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int. 2001;59:260-9.
6. Zhou S, Zhao P, Li Y, Deng T, Tian L, Li H. Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism. Eur J Pharmacol. 2014;740:9-14.
7. Sandhu S, Wiebe N, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006-16.
8. Geng Q, Ren J, et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114(4):562-70.
9. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, CARDS Investigators. . Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54(5):810-9.
10. Abe M, Maruyama N, Okada K, Metsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb. 2011;18(11):1018-28.
11. Dalla Nora E, Passaro A, Zamboni PF, et al. Atorvastatin improves metabolic control and endothelial function in type diabetic patients: a placebo-controlled study. J Endocrinol Invest. 2003;26:73-8.
12. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications. 2001;15(3):113-9.
13. Hommel E, Andersen P, Gall M-A, Nielsen F, Jensen B, Rossing P, Dyerberg J, Parving H-H. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992;35:447-51.
14. Lam KSL, Cheng IKP, Janus ED, et al. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia. 1995;38:604-9.
15. Nielsen S, Schmitz O, Molle N, et al. Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 1993;36:1079-86.
16. Zhang A, Vertommen J, Van Gaal L, et al. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract. 1995;29:189-94.
17. Tonolo G, Calvia P, Ciccarese M, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997;20(12):1891-5.
18. Nakamura T, Ueda Y, Sugaya T, et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005;28(11):2728-32.
19. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001;21(6):449-54.
20. Wu G, Gao X, Changlin M. Clinical Observe Effect of Atorvastatin Combined with Benazepril Treatment of Early Diabetic Nephropathy. China Academic J Electronic Publishing House. 2013;14(2):117-9.
21. Xiaoli D, Shen J, Ting L. Lipitor and emberd combined treat the blood lipids of diabetic nephropathy. Sichun MEdical Journal. 2015;36(3):404-6.
22. Qun X, Qiang Y, Ye D, et al. The split or combination of Simvastatin and bei treat diabetic nephropathy. China New Drugs. 2005;24(6):440-3.
23. Jabir NR, Siddiqui AN, Firoz CK, Md Ashraf G, Zaidi SK, Khan MS, Shakil S, Alama MN, Kamal MA, Tabrez S. Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases. Curr Pharm Des. 2016;22(5):566-71.
24. Vázquez-Pérez S, Aragoncillo P, de Las HN, et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant. 2001;16 suppl 1:40-4.
25. Hunt LP, Short CD, Mallick NP. Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int. 1988;34(3):382-8.
26. Geng Q, Ren J, Song J, Li S, Chen H. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114(4):562-70.
27. Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, Zhang H. Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016;67(6):881-92.
28. Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(7):e0132970.
29. Douglas K, O'Malley PG, Jackson JL. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med. 2006;145(2):177-24.
30. Satirapoj B, Promrattanakun A, Supasyndh O, Choovichian P. The Effects of Simvastatin on Proteinuria and Renal Function in Patients with Chronic Kidney Disease. Int J Nephrol. 2015;2015:485839.
31. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int. 2000;75:S27-31.
32. Nikolic D, Banach M, Nikfar S, Salari P, Mikhailidis DP, Toth PP, Abdollahi M, Ray KK, Pencina MJ, Malyszko J, Rysz J, Rizzo M, Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168(6):5437-47.
33. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis. 2008;200(1):1-12.
34. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G. How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol. 2002;13:2898-908.
35. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome. A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant. 2007;22(1):118-27.
36. Phillips AO, Steadman R. Diabetic nephropathy: the central role of renal proximal tubular cells in tubulointerstitial injury. Histol Histopathol. 2002;17(1):247-52.
37. Hou W, Lv J, Perkovic V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and metaanalysis. Eur Heart J. 2013;34(24):1807-17.
38. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005;96(9):1290-2.